comparemela.com

Latest Breaking News On - Scintomics gmbh - Page 6 : comparemela.com

Blue Earth Diagnostics Highlights Upcoming Presentation of Additional Results from Investigational Phase 3 LIGHTHOUSE Study

Results of the Investigational Phase 3 LIGHTHOUSE Study of 18F-rhPSMA-7.3 in newly diagnosed prostate cancer to be presented at 2023 ASCO Genitourinary Cancers Symposium (ASCO GU)

United statesSan franciscoScintomics gmbBrianf chapinUniversity of texas md anderson cancer centerStudy groupDivision of surgeryTechnical university of munichDuke university medical centerDepartment of urologyBlue earth diagnostic medical affairsBlue earth diagnosticsCancers symposiumProstate specific membrane antigen targetedEmission tomographyAdvanced prostate cancer

Blue Earth Diagnostics Announces Efficacy and Safety Results from Phase 3 LIGHTHOUSE Trial of Investigational PET Imaging Agent 18F-rhPSMA-7 3 in Newly Diagnosed Prostate Cancer

First results from LIGHTHOUSE trial presented at 23rd Annual Scientific Meeting in Urologic Oncology (SUO)

San diegoUnited statesScintomics gmbDavide gaudenBrianf chapinTechnical university of munichDivision of surgeryUniversity of texas md anderson cancer centerDepartment of urologyDrug administrationStudy groupBlue earth diagnosticsProstate specific membrane antigen targetedAnnual scientific meetingUrologic oncologyAssociate professor

Blue Earth Diagnostics Announces Efficacy and Safety Results from Phase 3 LIGHTHOUSE Trial of Invest

− First results from LIGHTHOUSE trial presented at 23rd Annual Scientific Meeting in Urologic Oncology (SUO) –MONROE TOWNSHIP, N.J. & OXFORD, England (BUSINESS WIRE) Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today.

United statesUnited kingdomSan diegoScintomics gmbDavide gaudenBrianf chapinClare gidleyMike beyerPriscilla harlanUniversity of texas md anderson cancer centerDrug administrationStudy groupSam brown incBracco groupDivision of surgeryTechnical university of munich

Blue Earth Diagnostics Announces Efficacy and Safety Results from Phase 3 LIGHTHOUSE Trial of Investigational PET Imaging Agent 18F-rhPSMA-7 3 in Newly Diagnosed Prostate Cancer

- First results from LIGHTHOUSE trial presented at 23rd Annual Scientific Meeting in Urologic Oncology (SUO) - Blue Earth Diagnostics, a Bracco company and recognized leader in the development and

United statesUnited kingdomSan diegoScintomics gmbKostenloser wertpapierhandelDavide gaudenBrianf chapinClare gidleyMike beyerPriscilla harlanUniversity of texas md anderson cancer centerDrug administrationStudy groupSam brown incBracco groupDivision of surgery

Blue Earth Diagnostics Announces Results on Clinical Factors Impacting Detection Rates from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA-7 3 in Biochemical Recurrence of Prostate Cancer

Oral presentation highlighted at American Society for Radiation Oncology (ASTRO) 2022 Annual Meeting

United statesSan antonioScintomics gmbDavide gaudenBenjamin lowentrittTechnical university of munichAmerican society for radiation oncologyDrug administrationStudy groupChesapeake urology research associatesBlue earth diagnosticsProstate specific antigenProstate specific membrane antigen targetedAmerican societyRadiation oncologyNew drug application

vimarsana © 2020. All Rights Reserved.